Joe Gramigna News Today : Breaking News, Live Updates & Top Stories | Vimarsana

WEST PALM BEACH, Fla. — Spinal cord atrophy appeared to predict silent progression in relapse-onset MS, according to results of a single-center observational study presented at ACTRIMS Forum.“Understanding progressive disease is an important challenge in MS,” Antje Bischof, MD, of the department of neurology and institute of translational neurology at the University Hospital

A digital medicine system appeared to improve clinical schizophrenia symptoms beyond the effects of oral pharmacotherapy alone, according to study results presented at Psych Congress. “This work uses data from a digital medicine system that consists of tablets of the atypical antipsychotic aripiprazole, embedded with an ingestible event marker,” J. Corey Fowler, PhD, director of

Patients with severe mental illness, particularly those with schizophrenia who are insured by Medicaid, have significant social risk factors that may adversely affect overall health, according to a study presented at Psych Congress.“More than 5% of adults in the United States have severe mental illness, including bipolar type I, major depressive disorder and schizophrenia,” Dusica

Schizophrenia’s approximate societal burden was $341.5 billion in the U.S. in 2019, according to study results presented at Psych Congress.Adjusted for inflation, this represented a 99.8% increase in burden since 2013.

LXB improved all measures of function and work productivity among patients with idiopathic hypersomnia, according to findings presented at the American Neurological Association Annual Meeting.The treatment (calcium, magnesium, potassium and sodium oxybates; Jazz Pharmaceuticals Inc.), also referred to as lower-sodium oxybate (LXB) and Xywav, has the same active moiety at the same concentration as